Vericel Corporation $VCEL Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its stake in Vericel Corporation (NASDAQ:VCEL) by 25.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,279 shares of the biotechnology company’s stock after selling 5,200 shares during the period. Handelsbanken Fonder AB’s holdings in Vericel were worth $650,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in VCEL. Ameritas Advisory Services LLC bought a new position in shares of Vericel during the second quarter worth about $30,000. CWM LLC lifted its position in Vericel by 101.3% in the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 694 shares during the last quarter. AlphaQuest LLC acquired a new position in Vericel during the 2nd quarter valued at about $60,000. Gagnon Securities LLC bought a new position in Vericel in the 1st quarter worth about $137,000. Finally, US Bancorp DE grew its position in Vericel by 29.9% in the 1st quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 706 shares during the last quarter.

Vericel Stock Performance

Shares of NASDAQ VCEL opened at $40.20 on Friday. Vericel Corporation has a 1 year low of $29.24 and a 1 year high of $63.00. The firm has a market cap of $2.03 billion, a P/E ratio of 335.03 and a beta of 1.41. The stock has a fifty day moving average price of $35.86 and a two-hundred day moving average price of $37.69.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $64.57 million. During the same quarter in the previous year, the business earned ($0.02) EPS. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. Vericel has set its FY 2025 guidance at EPS. On average, research analysts predict that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VCEL has been the topic of a number of recent analyst reports. Zacks Research cut Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Truist Financial reiterated a “buy” rating and set a $50.00 price target (up previously from $41.00) on shares of Vericel in a research report on Monday, November 10th. BTIG Research cut Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a report on Tuesday. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $58.75.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.